GSK’s Lamictal Extended Release Is “Approvable” At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency is seeking additional analyses of data used to support the sNDA for the epilepsy drug.
You may also be interested in...
GSK And Valeant Partner On Epilepsy Candidates
$125 million upfront deal could ameliorate impact of 2010 Lamictal patent expiry for GSK.
GSK And Valeant Partner On Epilepsy Candidates
$125 million upfront deal could ameliorate impact of 2010 Lamictal patent expiry for GSK.
Sepracor Licenses Late-Stage Anti-Epileptic From Portuguese Pharma Bial
Late 2008/early 2009 NDA filing targeted for the new chemical entity as an adjunct therapy to improve control of epileptic seizures.